ARS Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SPRY, updated each market day.
SPRY AI Sentiment
AI sees no strong directional signal for ARS Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About ARS Pharmaceuticals, Inc. Common Stock
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Sector
Exchange
Market Cap
$821,188,728
Cap Tier
Employees
163
Headquarters
SAN DIEGO, CA
Listed Since
Nov. 9, 2022
Website
SPRY Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SPRY Volatility
ARS Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
